Published in J Clin Invest on July 18, 2014
Placebo-induced changes in FMRI in the anticipation and experience of pain. Science (2004) 8.33
Behavioral theories and the neurophysiology of reward. Annu Rev Psychol (2006) 7.61
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies. Neuroimage (2008) 5.01
Placebo and opioid analgesia-- imaging a shared neuronal network. Science (2002) 4.57
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci (2006) 3.87
The functional neuroanatomy of the placebo effect. Am J Psychiatry (2002) 3.26
Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J Neurosci (2006) 3.25
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
The cerebellum in Parkinson's disease. Brain (2013) 3.06
Placebo in emotional processing--induced expectations of anxiety relief activate a generalized modulatory network. Neuron (2005) 2.90
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab (2006) 2.42
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
A prefrontal non-opioid mechanism in placebo analgesia. Pain (2010) 2.14
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci (2008) 1.47
Do "placebo responders" exist? Contemp Clin Trials (2008) 1.35
Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One (2012) 1.21
Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage (2006) 1.21
Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. Exp Neurol (2009) 1.12
Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum Brain Mapp (2011) 1.10
Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol (2009) 1.05
Network modulation following sham surgery in Parkinson's disease. J Clin Invest (2014) 0.89
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Are patients with social developmental disorders prosopagnosic? Perceptual heterogeneity in the Asperger and socio-emotional processing disorders. Brain (2004) 1.51
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry (2010) 1.45
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Information processing during face recognition: the effects of familiarity, inversion, and morphing on scanning fixations. Perception (2006) 1.36
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Mov Disord (2003) 1.28
The placebo effect in Parkinson's disease. Trends Neurosci (2002) 1.24
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
The placebo effect in neurological disorders. Lancet Neurol (2002) 1.18
Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks. Biol Psychiatry (2002) 1.10
Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol (2008) 1.10
Functional imaging in Parkinson disease. Neurology (2008) 1.08
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry (2004) 1.06
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord (2006) 1.03
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord (2013) 1.02
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008) 1.00
Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol (2004) 0.98
Developmental prosopagnosia: a study of three patients. Brain Cogn (2003) 0.96
The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof (2002) 0.94
Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord (2008) 0.94
Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol (2007) 0.93
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain (2004) 0.92
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res (2004) 0.90
The effects of exercise on cognition in Parkinson's disease: a systematic review. Transl Neurodegener (2014) 0.89
Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther (2013) 0.89
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One (2012) 0.88
The biochemical bases of the placebo effect. Sci Eng Ethics (2004) 0.88
What is perseverated in schizophrenia? Evidence of abnormal response plasticity in the saccadic system. J Abnorm Psychol (2005) 0.86
Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol (2007) 0.86
The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One (2013) 0.85
Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse (2009) 0.85
Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog Brain Res (2010) 0.84
Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. Mov Disord (2004) 0.84
Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse (2010) 0.83
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord (2009) 0.83
Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol (2005) 0.83
DNAJC13 genetic variants in parkinsonism. Mov Disord (2014) 0.83
Is there seasonal variation in risk of Parkinson's disease? Mov Disord (2007) 0.82
Investigations of face expertise in the social developmental disorders. Neurology (2007) 0.82
Joubert syndrome surviving to adulthood associated with a progressive movement disorder. Mov Disord (2007) 0.82
PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry (2002) 0.82
Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse (2003) 0.82
In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. J Cereb Blood Flow Metab (2012) 0.81
Impaired spatial coding within objects but not between objects in prosopagnosia. Neurology (2005) 0.81
In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Mov Disord (2014) 0.81
Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients. Ann N Y Acad Sci (2002) 0.81
Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Mov Disord (2014) 0.81
The covert priming effect of faces in prosopagnosia. Neurology (2004) 0.81
Novel spatial analysis method for PET images using 3D moment invariants: applications to Parkinson's disease. Neuroimage (2012) 0.80
Etiology of Parkinson's disease. Can J Neurol Sci (2003) 0.80
Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord (2012) 0.79
Perceptual functions in prosopagnosia. Perception (2004) 0.79
Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. EJNMMI Res (2013) 0.79
Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem (2009) 0.79
Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience (2003) 0.79
GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol (2006) 0.78
Imaging neural correlates of mild cognitive impairment in Parkinson's disease. Lancet Neurol (2012) 0.78
Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans. J Neurosci (2013) 0.78
Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. Can J Neurol Sci (2005) 0.77
Scan patterns during the processing of facial identity in prosopagnosia. Exp Brain Res (2007) 0.77
Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism. Mov Disord (2012) 0.77
Parkinson's disease: imaging update. Curr Opin Neurol (2002) 0.76
Biomarkers for trials of neuroprotection in Parkinson's disease. Mov Disord (2012) 0.76
Rett syndrome: investigation of nine patients, including PET scan. Can J Neurol Sci (2002) 0.76
Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. Mov Disord (2006) 0.75
Continuous dopaminergic therapy in Parkinson disease: time to stride back? Ann Neurol (2010) 0.75
Treatment for the progression of Parkinson's disease. Lancet Neurol (2005) 0.75
Scans without evidence of dopamine deficiency: the triumph of careful clinical assessment. Mov Disord (2010) 0.75
Neurology in Canada: history of the Canadian Neurological Society. Neurology (2013) 0.75
The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia. Exp Brain Res (2004) 0.75
Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Ann Neurol (2005) 0.75
"Stiff in the closet"--who provides care for Parkinsonian patients? Can J Neurol Sci (2002) 0.75
Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. Neuropsychologia (2013) 0.75
[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. Mov Disord (2002) 0.75
The Saskatchewan Movement Disorders Program: Commitment Pays Off. Can J Neurol Sci (2015) 0.75
Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. Camb Q Healthc Ethics (2016) 0.75